Available to passage freely in academic laboratory*
Receive 5 NSG™ mice at no additional cost for
each PDX Live™ model purchased.**
Highly characterized, clinically relevant models.
Primary Site | Model ID | AKA |
---|---|---|
Bladder | TM00016 | BL0293 |
Breast | TM00098 | BR1126F |
TM00089 | BR0620F | |
TM00386 | BR0555F | |
TM00096 | BR0851F | |
Colon | TM00170 | CN1572F |
Head | TM01141 | |
Lung | TM00302 | LG1306aF |
TM00219 | LG1049F | |
TM00233 | LG1202 | |
TM00193 | LG0591F | |
TM00194 | LG0627PE | |
TM00199 | LG0703F | |
Ovary | TM00335 | OV1828F |
Pancreas | TM01212 | TM01212F |
Prostate Gland | TM00298 | PR1996F |
Skin | J000106560 | PS4050 |
Additional live models may be available, and are subject to change.
For specific model availability, please contact:
Technical Information Services
micetech@jax.org
1-800-422-6423 (US, Canada & Puerto Rico)
1-207-288-5845 (from any location)
JAX Technical Support
Study Type | Arms | Vehicle | SOC | Drug A | Drug B | Combination Drug A+B |
---|---|---|---|---|---|---|
1. Pilot efficacy study | 3 | 1 | 1 | 1 | 0 | 0 |
2. Dose response | 5 | 1 | 1 | 3 | 0 | 0 |
3. Drug combination | 4 | 1 | 0 | 1 | 1 | 1 |
4. Tolerability | 3 | 1 | 0 | 2 | 0 | 0 |
We provide you data in weeks with study-ready clinically relevant patient-derived xenografts in the most robust mouse models.
Contact Technical Support
micetech@jax.org
1.800.422.6423 (US)
1.207.288.5845 (International)
Figure 1. Mice bearing passage 3 colon adenocarcinoma PDX tumor (TM00170) were treated with vehicle control: D5W (dark grey), 20mg/ kg 5-Fu (light blue), 10mg/kg Oxaliplatin (orange) and 5-Fu + Oxaliplatin (dark blue) once per week for 3 weeks. Vehicle and 5-Fu were administrated intravenously and Oxaliplatin was dosed intraperitoneally. The readout for compound efficacy–alone or in combination-was assessed by taking tumor caliper measurements and body weight twice weekly. Ten NSG™ mice were used per arm.
Figure 2. Mice bearing passage 4 TM00089 PDX tumor were treated with vehicle control (D5W), Cisplatin (2mg/kg), Cyclophosphamide (40mg/kg) and Doxorubicin (2mg/kg) intravenously, once per week for 3 weeks; Docetaxel (15mg/kg) was dosed once per week only for 2 weeks intravenously.
Figure 3. A) Patient tumor for PDX model TM00089 (aka, BR0620); PR marker (negative). B) P0 tumor #037 for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker. C) P1 tumor for PDX model TM00089 (aka, BR0620F); estradiol supplemented; PR marker (negative)
Figure 4. Mice bearing TM00199 PDX samples at passage 3 were used to create five treatment groups of twelve mice each: vehicle control (0.5 % carboxymethylcellulose); erlotinib (50 mg/kg); afatinib (20 mg/kg); cetuximab (10 mg/kg); and afatinib plus cetuximab (20 mg/kg and 10 mg/kg, respectively). Vehicle, erlotinib, and afatinib were IP dosed daily for 21 days. Cetuximab was dosed intravenously three times weekly, for three weeks. Mice were monitored for tumor volume.
Figure 5. A) P1 tumor #940_001 for PDX model TM00199 (aka, LG0703F). B) P1 tumor #940_006 for PDX model TM00199 (aka, LG0703F).